Antibody neutralizing human respiratory syncytial virus

Patent metadata

Field	Value
Publication number	US-11008380-B2
Application number	US-201916434729-A
Country	US
Kind code	B2
Filing date	Jun 7, 2019
Priority date	Oct 29, 2015
Publication date	May 18, 2021
Grant date	May 18, 2021

Abstract

The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.

First claim

The invention claimed is:

1. An antibody or antigen binding fragment that binds or interacts with an epitope on human RSV pre-fusion or human RSV post-fusion F proteins, wherein the epitope on the human RSV F protein comprises the following amino acids set forth in Genbank Accession Number AAR14266: an asparagine at position 426 (Asn 426), an arginine at position 429 (Arg 429), an isoleucine at position 432 (Iso 432), a lysine at position 433 (Lys 433), and a lysine at position 445 (Lys 445),
wherein the antibody or antigen binding fragment comprises a light chain variable region and a heavy chain variable region, and
wherein the antibody or antigen binding fragment does not comprise a light chain variable region having the amino acid sequence set forth in SEQ ID NO:8 and a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:9.

2. The antibody or antigen binding fragment of claim 1 , wherein the human RSV pre-fusion F protein is a trimer of F protein monomers and when the antibody or antigen binding fragment is bound to the epitope, the light chain of the antibody or antigen binding fragment packs against a glutamic acid at position 161 (Glu 161) and a serine at position 182 (Ser 182) of the neighboring monomer of the RSV pre-fusion trimer of the F protein.

3. The antibody or antigen binding fragment of claim 1 , wherein the antibody or antigen binding fragment
(i) binds to the human RSV pre-fusion F protein with a Kd value of about 1×10 −9 M to about 1×10 −12 M as determined by surface plasmon resonance;
(ii) binds to the human RSV post-fusion F protein with a Kd value of about 1×10 −9 M to about 1×10 −11 M as determined by surface plasmon resonance; or
(iii) binds to the human RSV pre-fusion F protein with a Kd value of about 1×10 −9 M to about 1×10 −12 M as determined by surface plasmon resonance and binds to the human RSV post-fusion F protein with a Kd value of about 1×10 −9 M to about 1×10 −11 M as determined by surface plasmon resonance.

4. An antibody or antigen binding fragment that cross-blocks or competes with an isolated antibody comprising a light chain variable region having the amino acid sequence set forth in SEQ ID NO: 8 and a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 7 for binding to an epitope of human RSV pre-fusion or post-fusion F protein having the amino acid sequence set forth in Genbank Accession Number AAR14266,
wherein the antibody or antigen binding fragment comprises a light chain variable region and a heavy chain variable region, and
wherein the antibody or antigen binding fragment has at least one of the following characteristics:
(i) binds to a human RSV pre-fusion F protein with a Kd value of about 1×10 −9 M to about 1×10 −12 M as determined by surface plasmon resonance;
(ii) binds to a human RSV post-fusion F protein with a Kd value of about 1×10 −9 M to about 1×10 −11 M as determined by surface plasmon resonance; or
(iii) binds to a human RSV pre-fusion F protein with a Kd value of about 1×10 −9 M to about 1×10 −12 M as determined by surface plasmon resonance and binds to a human RSV post-fusion F protein with a Kd value of about 1×10 −9 M to about 1×10 −11 M as determined by surface plasmon resonance, wherein the antibody or antigen binding fragment that cross-blocks or competes with the isolated antibody is not the isolated antibody comprising a light chain variable region having the amino acid sequence set forth in SEQ ID NO: 8 and a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 9.

5. The antibody or antigen binding fragment of claim 4 , wherein the epitope comprises the following amino acids set forth in Genbank Accession Number AAR14266: an asparagine at position 426 (Asn 426), an arginine at position 429 (Arg 429), an isoleucine at position 432 (Iso 432), a lysine at position 433 (Lys 433), and a lysine at position 445 (Lys 445).

6. The antibody or antigen binding fragment of claim 4 , wherein the human RSV pre-fusion F protein is a trimer of F protein monomers and when the antibody or antigen binding fragment is bound to the epitope, the light chain of the antibody or antigen binding fragment packs against a glutamic acid at position 161 (Glu 161) and a serine at position 182 (Ser 182) of the neighboring monomer of the RSV pre-fusion trimer of the F protein.

Assignees

• Merck Sharp & Dohme

Inventors

• Vora Kalpit A
• Cox Kara S
• Tang Aimin
• Chen Zhifeng
• Distefano Daniel
• Zhang Lan
• Su Hua-Poo

Classifications

• C07K16/11 Primary

  Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV] · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title

• C07K2317/41

  Glycosylation, sialylation, or fucosylation · CPC title

• C07K2317/14

  Specific host cells or culture conditions, e.g. components, pH or temperature · CPC title

• A61K39/42

  viral · CPC title